Liver Disease clinical trials at UCSF
19 in progress, 11 open to eligible people
NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
open to eligible people ages 16 years and up
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease…
San Francisco, California and other locations
Bicalutamide Therapy in Young Women With NAFLD and PCOS
open to eligible females ages 18-42
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with…
San Francisco, California
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
open to eligible people ages 18 years and up
The study consists of a randomized controlled trial evaluating the efficacy and feasibility of a stepped alcohol treatment using telemedicine on unhealthy alcohol use in patients with chronic liver disease receiving care in hepatology practices at…
San Francisco, California and other locations
Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
open to eligible people ages 18-75
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body…
San Francisco, California and other locations
Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
open to eligible people ages 18-75
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can…
San Francisco, California and other locations
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
open to eligible people ages 30-70
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for …
San Francisco, California and other locations
Androgens and NAFLD Longitudinal Cohort Study
open to eligible females ages 18-42
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or…
San Francisco, California and other locations
Functional Assessment in Liver Transplantation
open to eligible people ages 18 years and up
This will be a prospective cohort study of patients with liver disease. Subjects will undergo geriatric assessments of frailty, functional status, and disability using functional status measures at baseline and at every clinic visit in the…
San Francisco, California and other locations
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
open to eligible people ages 18 years and up
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the progression of fatty …
San Francisco, California
Nonalcoholic Fatty Liver Disease in HIV Database
open to eligible people ages 18 years and up
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD…
San Francisco, California and other locations
Social & Contextual Impact on Children Undergoing Liver Transplantation
open to eligible people ages up to 70 years
The social determinants of health have a large impact on health. For example, neighborhood socioeconomic deprivation is associated with increased risk of medication non-adherence, graft failure, and death in children after liver transplant. In order …
San Francisco, California and other locations
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Sorry, currently not accepting new patients, but might later
Cholestasis is a condition in which bile is not properly transported from the liver to the small intestine. Cholestasis can be caused by an array of childhood diseases, including the genetic diseases Alagille syndrome (ALGS), alpha-1 antitrypsin…
San Francisco, California and other locations
Longitudinal Study of Mitochondrial Hepatopathies
Sorry, currently not accepting new patients, but might later
The specific aims of this study are (1) to determine the clinical phenotypes and natural history of hepatic RC and FAO disorders, (2) to determine the correlation between genotype and phenotype, (3) to determine if circulating biomarkers reflect…
San Francisco, California and other locations
Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Sorry, in progress, not accepting new patients
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which…
San Francisco, California and other locations
Vitamin E Dosing Study
Sorry, in progress, not accepting new patients
This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).
San Francisco, California and other locations
Database of Infants With Cholestasis
Sorry, not currently recruiting here
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease…
San Francisco, California and other locations
Genetic Collection Protocol
Sorry, not currently recruiting here
This study involves the one-time collection of whole blood or saliva samples for the extraction and storage of DNA for use in ongoing and future ChiLDReN studies.
San Francisco, California and other locations
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Sorry, in progress, not accepting new patients
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of…
San Francisco, California and other locations
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
Sorry, not currently recruiting here
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. NAFLD is the most…
San Francisco, California and other locations
Our lead scientists for Liver Disease research studies include Michael Ohliger, MD Bilal Hameed, MD Monika Sarkar Jennifer Price, MD Jennifer C Lai, MD, MBA Mandana Khalili, M.D. Sharad Wadhwani, MD, MPH.
Last updated: